MedWellAI, Inc. FY 2026: Revenue $527.9K, EPS $(0.24) — 10-K Summary
MedWellAI, Inc. reported FY 2026 revenue of $527,857, down 11.2% YoY, and a net loss of $1,589,465, improved from FY 2025. EPS was $(0.24), better than $(0.49) in 2025. The company shifted focus to health and wellness e-commerce, acquired a 51% stake in Healthy Lifestyle, and exited online direct sales due to regulatory challenges.
How this was made
The 30-second read
Why it matters
Regulatory headwinds reduced commission revenue and effectively ended online direct sales, while the company shifted toward GLP-1 and in-office products and launched a 503B pharmacy platform; investors will likely focus on whether this pivot can restore revenue and stabilize losses.
Market read
A small-cap turnaround print with explicit regulatory-driven channel changes and continued losses, likely informing near-term positioning rather than creating a new catalyst beyond the filing.
What to watch
The summary does not quantify cash balance, guidance, or the profitability trajectory of the new GLP-1 and 503B pharmacy initiatives, which could dominate the stock reaction.
Background
The piece summarizes MedWellAI’s FY2026 10-K, including a strategic pivot from digital asset mining to health and wellness e-commerce and related discontinued operations.
Ticker impact
MedWellAI reports FY2026 revenue of $527.9K and diluted loss per share of $(0.24), plus a pivot away from online direct sales due to regulatory hurdles.
Likely downside or continued volatility as investors weigh regulatory headwinds and the credibility/timing of the GLP-1 e-commerce and 503B pharmacy pivot.
The article discloses a full-year financial print with revenue decline and continued net losses, alongside concrete operational changes (online channel exit, pivot, impairments/discontinued operations) that typically increase uncertainty for small-cap turnaround stories.
Market effects
Highlights regulatory friction for wellness/health-adjacent commerce channels and the potential need to shift to regulated pharmacy models.
No clear regional spillover described.
No global macro or cross-border market linkage described.
Counterpoint
The diluted loss per share improved versus FY2025, suggesting the pivot and discontinuations may be reducing burn even as revenue declines.
Key entities
- companyMedWellAI, Inc.
Subject of the FY2026 10-K summary, reporting revenue decline, improved but still sizable net loss, and a regulatory-driven channel exit plus business pivot.
